Aurobindo Pharma Inaugurates ₹10 Billion (USD 120M) TheraNym Biologics CDMO Plant in India, Expanding Capacity by 25,000L

Sahi India

Overview

Aurobindo Pharma announced the inauguration of its state-of-the-art ₹10 billion (approx. USD 120 million) TheraNym biologics CDMO facility in Hyderabad, India. This plant adds 25,000 liters of mammalian cell culture capacity, strengthening the company’s global supply chain position in biosimilars and the CDMO segment. As one of the largest investments in mammalian cell culture capacity in India, it positions Aurobindo as a major player in the high-growth global biologics CDMO market.

In Depth

Key Findings

Aurobindo Pharma has announced the operational launch of its state-of-the-art biologics Contract Development and Manufacturing Organization (CDMO) facility, ‘TheraNym,’ built with an investment of ₹10 billion (approximately USD 120 million) in Hyderabad, India. This new plant boasts a total mammalian cell culture capacity of 25,000 liters, significantly strengthening the company’s global position in biosimilars and the CDMO services sector.

Technical / Clinical Details

The TheraNym facility is equipped with multiple manufacturing lines and advanced mammalian cell culture equipment, including 2,000L, 5,000L, and 10,000L single-use bioreactors. The plant is designed to provide end-to-end cGMP (current Good Manufacturing Practice) services, from drug substance manufacturing for monoclonal antibodies, recombinant proteins, and other complex biologics, to drug product formulation, fill-finish, and packaging. Advanced automation systems and stringent quality control processes are implemented to ensure high-quality and efficient manufacturing. This addition of 25,000 liters of capacity represents one of the largest private investments in mammalian cell culture capacity in a single facility in India, establishing a flexible system capable of meeting large-scale production demands from clients.

Background & Context

The biopharmaceutical market continues its rapid global growth, driven by increasing demand for new biological therapeutics for cancer, autoimmune diseases, and rare diseases. Concurrently, the demand for CDMOs that support the development and manufacturing of biopharmaceuticals is also rising. India has a strong foundation in the pharmaceutical industry and is a major player, especially in the biosimilar market. Aurobindo Pharma’s investment in the TheraNym plant signifies India’s growing role as a global hub for biopharmaceutical manufacturing, providing advanced technology and large-scale production capacity.

Strategic Significance & Outlook

The operationalization of the TheraNym plant is a crucial step for Aurobindo Pharma to enhance its competitiveness as a major player in the global biologics CDMO market. This expanded manufacturing capacity will enable global pharmaceutical companies to bring biopharmaceuticals to market more quickly and efficiently, ultimately contributing to delivering life-saving medicines to more patients worldwide. The company aims to achieve sustained growth in the manufacturing of biosimilars and innovative biopharmaceuticals, and to expand its market share in the high-growth CDMO market.